Assessing the risk of epstein-barr virus-related lymphoproliferative disorders before administration of visilizumab.
Guthery
Stephen L
SL
Gross
Thomas G
TG
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D004279:DNA, Viral / Q000097:blood; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000175:diagnosis; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000139:chemically induced* / Q000821:virology; D018579:Patient Selection; D013601:T-Lymphocytes / Q000187:drug effects / Q000821:virology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004279:DNA, Viral; D005765:Gastrointestinal Agents; C456519:visilizumab